Ilagrit Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Ilaprazole 10 mg, designed for the effective management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and facilitating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Ilaprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, contributing to the healing of acid-related mucosal damage and providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), peptic ulcer disease, and erosive esophagitis. The synergistic action of Levosulpiride and Ilaprazole in Ilagrit Capsule addresses both motility dysfunction and acid hypersecretion, making it suitable for patients with functional dyspepsia, GERD, and other acid-peptic disorders. Ilagrit Capsule should be administered under medical supervision, with dosage tailored to individual patient needs. Caution is advised in patients with a history of hypersensitivity to either component, and it is contraindicated in those with gastrointestinal hemorrhage or obstruction. Common side effects may include headache, dizziness, and mild gastrointestinal disturbances.